Baseline characteristics of responders and non-responders
| Responders (N=14) | Non-responders (N=5) | p Value | |
|---|---|---|---|
| Demographics | |||
| Age (years) | 68.7±9.1 | 71.8±4.2 | 0.53 |
| Male | 13 (93%) | 5 (100%) | 0.50 |
| Ischaemic heart disease | 8 (57%) | 3 (60%) | 0.52 |
| Hypercholesterolaemia | 10 (72%) | 4 (80%) | 0.49 |
| Hypertension | 7 (50%) | 2 (40%) | 0.53 |
| Chronic kidney disease | 4 (29%) | 4 (80%) | 0.20 |
| Diabetes | 5 (36%) | 1 (20%) | 0.49 |
| ECG/echocardiography | |||
| QRSd (ms) | 163.0±22.8 | 155.5±20.9 | 0.55 |
| LVEDV (mL) | 201.5±72.5 | 159.0±80.8 | 0.37 |
| LVESV (mL) | 156.5±57.3 | 116.4±68.2 | 0.23 |
| SV (mL) | 45.0±19.7 | 39.6±20.3 | 0.30 |
| EF (%) | 25.6±8.0 | 25.8±8.5 | 0.44 |
| Medications (%) | |||
| ACE-I/ARB | 13 (93) | 5 (100) | 0.24 |
| β-Blocker | 12 (86) | 5 (100) | 0.90 |
| Loop diuretic | 14 (100) | 5 (100) | 0.36 |
| MRA | 9 (64) | 4 (80) | 0.93 |
| Brachial diameter (mm) | |||
| Baseline | 4.43±0.67 | 4.40±0.63 | 0.94 |
| 6 months | 4.47±0.54 | 4.50±0.37 | 0.94 |
| 12 months | 4.56±0.57 | 4.71±0.36 | 0.56 |
ACE-I, ACE inhibitor; ARB, angiotensin receptor blocker; LVEDV, left ventricular end diastolic volume; LVESV, left ventricular end systolic volume; MRA, mineralocorticoid receptor antagonist; QRSd, QRS duration; SV, stroke volume.